For solid-state R&D of small molecule drugs, the XtalPi solution integrates several state-of-the-art technologies for crystal structure prediction, crystal structure determination, virtual screening of salts and cocrystals, as well as an advanced solid-state R&D experimental platform. The company is dedicated to creating the next-generation platform for solid-state R&D for small molecules by combining experimental screening and characterization with theoretical calculations and analyses, and providing novel solutions for the solid-state R&D. At XtalPi, we help our clients improve the quality and efficiency of solid-state R&D and reduce R&D risks and costs.
XtalPi and Singleron will simultaneously conduct target validation and drug discovery, pursuing multiple promising targets and research paths in parallel to boost the efficiency and success rate of novel targeted therapy R&D while lowering their costs.
Led by SoftBank Vision Fund, PICC Capital, and Morningside
Using XtalPi's ID4 platform, the companies will discover drug candidates for "undruggable" targets